Abstract 760P
Background
Although concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer, elderly patients are often intolerable to chemotherapy. It’s urgent to explore a suitable regimen for these population. Cervical squamous cell carcinoma (CSCC) is characterized by the high expression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized anti-EGFR monoclonal antibody with good safety. This study aimed to investigate the efficacy and safety of nimotuzumab plus radiotherapy in the treatment of elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC).
Methods
It’s a prospective, multicenter, and single-arm trial. Key inclusion criteria included aged ≥ 65 years, histologically diagnosed CSCC with clinical stage IB3-ⅣA, ECOG 0-2, and refusing chemotherapy. Patients received nimotuzumab with 200mg/w for 6 weeks, underwent radiotherapy, including intensity-modulated radiotherapy (IMRT), volumetric intensity modulated arc therapy (VMAT) (45-50.4Gy, 1.8-2.0Gy/f, 25-28f), and brachytherapy (HR-CTV D90, 80-85Gy). Brachytherapy combined with external beam radiotherapy was completed within 8 weeks. The current endpoints include objective response rate (ORR), complete response rate (CRR), disease control rate (DCR), and safety.
Results
This trial enrolled 122 elderly LACSCC patients from Nov 2021 to Jan 2023. The median age was 72.5 years old (range from 65 to 92) with clinical stage IB3-ⅣA. The addition of nimotuzumab to radiotherapy exhibited a significant improvement in short-term efficacy with ORR of 87.70% (107/122), CRR of 42.62% (52/122), and DCR of 92.62% (113/122). The partial response was 45.08% (55/122), progressive disease was 2.50% (3/122), and stable disease was 4.92% (6/122). So far, no drug-related adverse events have occurred.
Conclusions
Nimotuzumab plus radiotherapy provided significant improvements in ORR, CRR, and DCR in elderly patients with LACSCC. No drug-related adverse events were observed. Our results demonstrate that nimotuzumab combined with radiotherapy may provide a choice for this population with better efficacy and tolerance.
Clinical trial identification
NCT04976478.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11